Oragenics Inc. Common Stock (OGEN)

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Oragenics shares are trading lower by 47% during Wednesday's session. The company announced a $4.45 million public offering.

Oragenics just reported results for the second quarter of 2024.

Let's dive into the action on the US markets on Wednesday. Here are the most active stocks that are driving the market today.

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Oragenics completed a key study showing its nasal spray drug ONP-002 effectively targets brain-related nasal areas, setting the stage for Phase 2 trials in concussion treatment.

Oragenics completes the formulation and filling of its nasal spray drug, ONP-002, for concussion treatment, aiming to launch a Phase 2a trial.